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Introduction: Early onset isolated dystonia (DYT1) is linked to a three base pair deletion (ΔGAG) mutation in the
TOR1A gene. Clinical manifestation includes intermittent muscle contraction leading to twisting movements or
abnormal postures. Neuropathological studies on DYT1 cases are limited, most showing no significant abnormalities. In
one study, brainstem intraneuronal inclusions immunoreactive for ubiquitin, torsinA and lamin A/C were
described. Using the largest series reported to date comprising 7 DYT1 cases, we aimed to identify consistent
neuropathological features in the disease and determine whether we would find the same intraneuronal
inclusions as previously reported.
Result: The pathological changes of brainstem inclusions reported in DYT1 dystonia were not replicated in our
case series. Other anatomical regions implicated in dystonia showed no disease-specific pathological intracellular inclu-
sions or evidence of more than mild neuronal loss.
Conclusion: Our findings suggest that the intracellular inclusions described previously in DYT1 dystonia may not be a
hallmark feature of the disorder. In isolated dystonia, DYT1 in particular, biochemical changes may be more relevant
than the morphological changes.
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Dystonia is a common and heterogeneous neurological
disorder. Recently, dystonia has been defined as a move-
ment disorder characterized by sustained or intermittent
muscle contractions causing abnormal, often repetitive,
movements, postures, or both with genetic heterogeneity
reported. The term ‘dystonia musculorum deformans’
was proposed in 1911 to describe a disorder in children
with twisted postures, muscle spasms, gait abnormalities
and clonic, rhythmic jerking movements [1]. In childhood
onset cases dystonia tends to become generalized, while
remaining focal or segmental in adult onset cases [2]. A
newly proposed classification system classified dystonia
according to two axes: clinical characteristics and etiology* Correspondence: janice.holton@ucl.ac.uk
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unless otherwise stated.[3]. Dystonia linked to a 3 base pair deletion (ΔGAG) mu-
tation in exon 5 of the TOR1A gene on chromosome
9q34.11 is called DYT1 dystonia [4]. The new classifica-
tion system classified DYT1 dystonia as isolated dystonia
in which dystonia is the only clinical sign with the excep-
tion of tremor [3]. The prevalence of isolated dystonia was
estimated at 330 per million in Rochester, Minnesota [5]
and is about 152 per million in the European population
[6]. In DYT1 the inheritance is autosomal dominant with
the disease onset in childhood [7] and the most common
clinical features include muscle contractions affecting the
leg or arm, often progressing to generalized involvement
with severe disability [8]. The mutation has been identified
in many diverse ethnic groups [9,10] and has a low pene-
trance of 30–40% [10-12].
The TOR1A gene encodes a 332 amino acid protein,
torsinA, which has a cytoplasmic localization in cells.
TorsinA is widely expressed throughout the centralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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high levels in dopaminergic neurons of the substantia
nigra, locus coeruleus, Purkinje cells, cerebellar dentate
nucleus, basis pontis, thalamus, hippocampal formation,
oculomotor nuclei and frontal cortex [13-16]. The exact
function of torsinA remains unclear in humans. However,
mutant torsinA protein has been shown to have aberrant
cellular localization and impaired protein interactions and
is associated with defective synaptic vesicle formation and
altered development of neuronal pathways [17].
Much of the research in primary dystonia has focused
on the role of the basal ganglia in disease [18-20]. How-
ever, imaging studies of patients carrying a mutation in
TOR1A causing primary dystonia revealed an increase in
metabolic brain activity not only in the basal ganglia but
also in the cerebellum [21,22]. Neuropathological investiga-
tion of clinically diagnosed primary dystonia cases has been
generally disappointing with no specific abnormalities
observed [23]. In genetically confirmed DYT1 cases, no
evidence of neuronal loss, inflammation or altered lo-
calization of torsinA could be identified [15,23-26]. A
possible reduction in striatal dopamine and the size of
pigmented neurons in the substantia nigra have been
suggested [15,23,26]. The most interesting observation to
date has been the finding of perinuclear intraneuronal in-
clusions immunoreactive for ubiquitin, torsinA and lamin
A/C in the periaqueductal grey matter, cuneiform and
pedunculopontine nuclei [27]. Similar inclusions were re-
ported in some of the DYT1 mouse models produced by
expression of transgenic human torsinA but this has not
been a consistent finding [28,29]. The intriguing observa-
tion of brainstem inclusions in DYT1 cases has not, so far,
been replicated.
The aims of this current study were: 1) to report the
neuropathological features of seven previously unreported
genetically proven DYT1 cases, 2) to determine whether
any pathological features were consistently observed in all
cases and could be regarded as disease-related and 3) to
determine whether the perinuclear intracytoplasmic inclu-
sions previously described in DYT1 dystonia are a consist-
ent feature of the disease.
Materials and methods
Cases
This project was approved by the Joint Local Research
Ethics Committee of the National Hospital for Neurology
and Neurosurgery and the UCL Institute of Neurology.
Autopsy specimens of 7 DYT1 confirmed cases were
received from the Brain and Tissue Banks for Develop-
mental Disorders, Baltimore. Clinical details, macroscopic
findings and neuropathology reports were provided by the
institution. To our knowledge, none of the DYT1 cases
have been previously reported. Formalin fixed, paraffin
embedded brain tissue was available in all dystonia casesalthough systematic sampling of multiple regions for each
case was not possible due to the retrospective nature of
the study. Where possible the frontal and temporal cor-
tices, striatum, globus pallidus, thalamus, subthalamic
nucleus, cerebellum, midbrain, pons, and medulla were
investigated. Brain regions available for study in each
case are indicated in Additional file 1: Table S1. The mid-
brain was absent in cases 2 and 3 and was only partially
represented in case 6. The pons including the reticular for-
mation was present in all cases except case 6.
Genetics
DNA was extracted from frozen brain tissue (cerebellum
or frontal cortex) using DNeasy Blood and Tissue Kit
(Cat no 69504). Cases were sequenced for the recurring
ΔGAG mutation in exon 5 of TOR1A using standard
Sanger polymerase chain reaction sequencing on an ABI
3730XL machine (Applied Biosystems, Inc., Foster City,
CA, USA) and analyzed using Sequencher software.
Immunohistochemistry (IHC)
In brief, paraffin embedded tissue sections (7 μm) were cut
and stained using routine methods, including hematoxylin
and eosin, Gallyas silver and Luxol fast blue/cresyl violet.
IHC staining was performed according to a standard
avidin-biotin complex protocol using the following anti-
bodies: ubiquitin (1:200, Dako, Ely,UK), tau (1:600, AT8,
Autogen Bioclear, Calne, UK); AT100 (1:200, Innogenetics,
Gent, Belgium), glial fibrillary acidic protein (GFAP;
1:1,000, Dako), Aβ (1:200, Dako), α-synuclein (1:50,
Novacastra, Newcastle, UK), α-synuclein (1:1000, BD
Transduction Biolabs, Oxford, UK), p62 (1:100, BD Bio-
science, Oxford, UK), CD68 (1:150, Dako), and TDP-43
(1:2000, Protein Tech, Manchester, UK). Antibodies to
ubiquitin, p62, and tau required pretreatment by pressure
cooking in sodium citrate buffer, pH 6.0, for 10 minutes
before IHC staining. Sections to be used for IHC staining
with antibodies to α-synuclein and Aβ were treated with
formic acid for 30 minutes before pressure cooking as
described above. For GFAP IHC, pre-treatment with
proteinase K was used. Antibody binding sites were visual-
ized using the chromogen diaminobenzidine, and sections
were counterstained using Mayer’s hematoxylin.
Neuropathology assessment
The staining protocol was designed to detect intracellu-
lar inclusions as previously described in DYT1 dystonia
[27]. In all cases brain regions including the midbrain and
pons were stained with antibodies to ubiquitin and p62 to
assess the presence of intraneuronal inclusions [27]. Due
to limited tissue availability the periaqueductal grey matter
was not available in all cases (absent in cases 2, 3 and 6).
The pontine tegmentum was available in all cases except
case 6. Cases were systematically screened for additional
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parenchymal Aβ deposition was determined in the frontal
cortex and diffuse and mature plaque load was assessed
based on the criteria of the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) [30]. Neurofib-
rillary tangle (NFT) pathology was determined using tau
IHC and staged where possible according to the method
of Braak and Braak [31]. Vascular pathology was assessed
and tau, ubiquitin, and α-synuclein IHC were performed
in selected regions to exclude progressive supranuclear
palsy, corticobasal degeneration, Parkinson disease and
multiple system atrophy as described previously [32]. Where
brainstem Lewy bodies (LBs) were identified cortical LB
pathology was also determined [33].
Results
Genetics
Sanger sequencing confirmed that all the cases harbour
the ΔGAG mutation (p.303-/Glu304) in exon 5 of the
TOR1A gene which is a recurring mutation in DYT1
dystonia.
Clinical data
The demographic and clinical data for the cases are sum-
marized in Table 1.
Case 1: This Caucasian female (ΔGAG mutation carrier)
was 89 years old at death. Despite having a strong family
history of dystonia she was clinically unaffected. Her
grandson had torticollis. Her sister (case 2) and niece were
positive for the ΔGAG mutation. She had a medical history
of hypertension, coronary artery disease, arterial vascular
insufficiency involving left arm and developed cognitive
impairment.
Case 2: A Caucasian woman (ΔGAG mutation carrier)
who died at the age of 87 years had a past medical history
of hypertension, hyperlipidemia, coronary artery disease,
pulmonary embolism, hypothyroidism, osteoarthritis and
dementia. Although unaffected herself, she had a family
history of dystonia. Her sister (case 1) and niece were both
positive for ΔGAG mutation. She died following a right
middle cerebral artery infarction confirmed prior to death
by imaging studies.Table 1 Demographics and clinical details of DYT1 cases
Case Sex Ethnicity Phenotype Family history
1 F American Caucasian Non-manifesting +
2 F American Caucasian Non-manifesting +
3 F American Caucasian Affected -
4 F American Caucasian Non-manifesting +
5 F American Caucasian Affected +
6 F American Caucasian Non-manifesting N/A
7 M American Caucasian Non-manifesting N/A
N/A: not available.Case 3: This Caucasian female, positive for ΔGAG mu-
tation, had a clinical diagnosis of dystonia with life-long
disability. Dystonic symptoms started at the age of 9 or
10 and were slowly progressive. She had a similarly affected
sibling but no other family history was available. By 73 years
of age she was weak bilaterally in the upper and lower
limbs and wheelchair bound. Abnormal involuntary move-
ments affected both upper extremities. She complained of
progressive bilateral hearing loss and episodic problems
with her vision and speech. Neurological examination re-
ported no facial asymmetry, weakness in the both upper
and both lower extremities, more severe proximally than
distally. Deep tendon reflexes were diminished in the upper
extremities, but symmetrical. Sensory evaluation showed
intact pinprick and vibration sensation in both hands and
right foot but these were absent in the left leg. No obvious
cerebellar dysfunction was reported. She died at the age
of 77.
Case 4: A Caucasian female (ΔGAG mutation carrier) of
Jewish ancestry died at the age of 90 years. She had been
well until the age of 89 when she developed left sided
weakness, expressive aphasia and dysphagia secondary
to stroke. She also had intermittent confusion and para-
noia. MRI reportedly showed an infarct involving the right
internal capsule, thalamus and white matter. She did not
have a history of movement disorder; however, her grand-
son had a diagnosis of dystonia.
Case 5: A Caucasian female with a clinical diagnosis of
dystonia died at the age of 90 years. Her son had a con-
firmed ΔGAG mutation. No further medical history was
available.
Case 6: This Caucasian female was a ΔGAG mutation
carrier and died aged 88 years. No further medical history
was available.
Case 7: This Caucasian male (ΔGAG mutation carrier)
was unaffected by dystonia and died at the age of 75. No
further clinical history was available.Neuropathology assessment
A summary of the pathological findings is given in
Table 2.Age at onset, years Age at death, years Cause of death
N/A 89 Natural
N/A 87 Stroke





Table 2 Summary of pathological findings in DYT1 cases
Case Brain
weight (g)*
Infarction Aβ pathology Tau pathology Lewy body pathology SVD CAA Final neuropathological diagnosis*
D M
1 N/A - + - - - + - • moderate atherosclerosis of cerebral vessels
• mild neuronal loss and gliosis in hippocampus
between the CA1 region and the subiculum
• mild loss of Purkinje cells in the cerebellum
• mineralization of vessel walls in the dentate nucleus
• non-specific neurodegenerative changes
2 1110 globus pallidus + + - - +++ + • mild cerebral artery atherosclerosis
• right middle cerebral artery territory subacute infarct
• possible AD
3 1200 - - - - - - - • mild cortical atrophy
• small areas of infarction
• cerebral athero-arterio-arteriolosclerosis, remote
frontal white matter infarct
4 1010 globus pallidus +++ ++ + (cortex, striatum and brainstem) - + ++ • cerebral artho-arteriosclerosis (a) microinfarcts in
cerebral white matter, deep gray nuclei and
occipital cortex (b) macro infarct in right posterior
internal capsule and pulvinar
• hippocampal sclerosis
5 N/A midbrain tegmentum ++ ++ + (cortex, striatum and brainstem) ++ (cortical and brainstem) + - • diffuse LB disease (a) substantia nigra degeneration
with LBs (b) neocortical LBs (c) AD neuropathology
• cerebrovascular disease (a)numerous infartcs of
different ages (b) atherosclerotic disease of circle
of Willis arteries
6 1184 - ++ + + (cortex, striatum and brainstem) - + + • brain generalized atrophy
• focal acute (perimortem) petechial hemorrhages
7 N/A - - - + (brainstem) + (substantia nigra) - - • melanocytic neoplasm with diffuse leptomeningeal
and perineural spread
- = absent; + = occasional/mild; ++ =moderate; +++ = severe; N/A-not available; SVD- Small vessel disease; CAA- Cerebral amyloid angiopathy; Aβ: D-diffuse plaques, M-mature plaques; AD: Alzheimer’s disease; LB: Lewy
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The macroscopic details were available from the neuro-
pathology reports supplied by the brain bank providing
the case. In all the DYT1 cases the weight of the unfixed
brains was in the normal range [34] or mildly reduced
(range 1010 – 1200 g, data available for cases 2–4 and 6).
The blood vessels of the circle of Willis showed variable
atherosclerosis in all cases except case 7. Mild cerebral
cortical atrophy was evident in case 3 and generalized
brain atrophy consistent with age was described in case
6. At brain slicing the cortical ribbon was well preserved
in all cases. The ventricular system was unremarkable in
cases 3 and 4 but there was moderate dilatation in case 2.
Four cases showed cerebral infarction, this affected the
right middle cerebral artery territory in case 2, frontal
white matter in case 3, several infarcts of varying age
with unspecified distribution in case 5, and multiple re-
gions of cerebral white matter, occipital cortex and deep
grey nuclei in case 4. Case 7 was found to have a diffuse
leptomeningeal melanocytoma. Pigmentation of the sub-
stantia nigra and locus coeruleus was described in cases 2,
3, 4, and 6 where it was noted to be normal.
Histological findings
Examination of the midbrain and pons, represented in
all cases except cases 6, using ubiquitin and p62 IHC
showed no evidence of NCIs of similar distribution and
morphology to those previously associated with early-onset
DYT1 dystonia [27]. Moreover a detailed examination of
additional brain regions did not reveal similar inclusions in
other structures.
DYT1 cases were systematically assessed for other
neuropathological abnormalities. Neuronal loss was gener-
ally inconspicuous in the regions studied. There was mild
neuronal cell loss in the pigmented neurons of the sub-
stantia nigra pars compacta of case 1, 4, 5 and 7 and in the
locus coeruleus of case 2, 4 and 5. Mild to moderate
Purkinje cell loss was observed in the cerebellum of all
the cases. Mild to moderate gliosis of the striatum was
observed in all the cases and also in the substantia nigra of
cases 1, 4 5, 6 and 7 in which it was available for analysis.
The pontine base showed variable gliosis and this was se-
vere in case 3. Vascular pathology and ischemic damage in
the form of small vessel disease (SVD), cerebral amyloid
angiopathy (CAA) and infarction was assessed in all cases.
Cases 1, 4, 5 and 6 had mild SVD while this was severe in
case 2. CAA was mild in cases 2 and 6 and moderate in
case 4. Small areas of infarction were observed in 3 cases.
In cases 2 and 4 infarcts involved the globus pallidus and
in case 5 a small infarct was noted in the midbrain teg-
mentum. We used two different α-synuclein antibodies
for IHC in multiple regions to assess LB pathology. LBs
were observed in case 5 and rare LBs were observed in the
substantia nigra of case 7. Sparse diffuse Aβ plaques werenoted in the cortex of case 1. In cases 2, 4, 5 and 6 both
diffuse and mature cortical Aβ plaques were present. Tau
pathology in the form of NFTs and neuropil threads was
evident in four cases (cases 4, 5, 6 and 7).
No consistent abnormalities were noted in the brain
regions available for examination in this study including
the midbrain, striatum, globus pallidus, cerebellum, and
pons. Apart from limited Alzheimer’s and LB pathology
as described above, none of the cases were found to have
neuropathological features of any other neurodegenerative
disease. In particular, multiple system atrophy, progressive
supranuclear palsy and corticobasal degeneration were
excluded.
Additional file 1: Table S1 summarizes the semi-
quantitative findings of the histological features of the
seven DYT1 cases.Discussion
There are only five neuropathological studies of genetically
confirmed DYT1 mutation cases in the literature [23]. We
aimed to significantly contribute to the field of dystonia
research by assessing the largest case series of DYT1 yet
investigated to determine whether consistent neuropatho-
logical features could be identified as a hallmark of the
disease. This study also addressed the question of whether
neuronal perinuclear intracytoplasmic inclusions of the
type previously associated with early-onset DYT1 dystonia
could be confirmed in our cases [27].
We confirmed that all of the cases carry a 3-basepair
deletion (ΔGAG) in exon 5 of the TOR1A gene which is a
common mutation in DYT1 dystonia. Among the seven
cases studied, two cases (cases 3 and 5) were symptomatic
and five were asymptomatic carriers for DYT1 dystonia
(cases 1, 2, 4, 6, and 7). Using a similar IHC approach
to that applied in a previous neuropathological study of
DYT1 dystonia [27] we did not replicate the finding of
ubiquitin positive inclusions in the midbrain and pons
with the exception of inclusions that were also immu-
noreactive for tau or α-synuclein, representing NFTs and
LBs respectively. We also screened for intracellular inclu-
sions in other brain regions and could not demonstrate
abnormality other than sparse Alzheimer and LB path-
ology. The remaining pathological features identified in
the cases were those of gliosis, mild-moderate Purkinje
cell depletion, CAA, SVD of varying severity and cerebral
infarcts. None of these changes can be regarded as disease
specific and are most likely to be due to the advanced age
at death of the cases (75–90 years).
We examined anatomical regions implicated in dystonia
and found no pathological intracellular inclusions or evi-
dence of more than mild neuronal loss in the caudate,
putamen, subthalamic nucleus, thalamus, pigmented neu-
rons of the substantia nigra and globus pallidus, other
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cases [35].
The reason that we failed to replicate the findings of
McNaught et al. [27] is uncertain. With the exception of
case 4 in the McNaught series, who was aged 33 years at
death, the ages of our 2 case series were similar exclud-
ing the possibility that the inclusions observed are age
related. One difference between the two studies is that
all four cases described by McNaught et al. manifested
clinical dystonia compared with only two cases in our
series, the remaining five cases that we investigated were
non-manifesting carriers of the gene mutation. If the
neuronal inclusions are only present in patients with clin-
ical dystonia this may have reduced the likelihood that we
would have detected inclusions in our cases. However,
similar electrophysiological and functional imaging ab-
normalities have been reported in cortical motor circuits of
manifesting and non-manifesting DYT1 carriers [36,37].
An alternative explanation could be that different anti-
bodies were used in the two studies and this remains a
possibility. Given the limitation that only a small amount
of tissue was available for study we chose ubiquitin and
p62 as screening antibodies as they target abnormally
folded proteins for degradation by the proteasome and au-
tophagy respectively. As both are sensitive markers of in-
clusions formed from a wide variety of different proteins
in neurodegenerative diseases and can recognise protein-
aceous inclusions for which the principle protein compo-
nent has not been identified we argued that if DYT1
dystonia is associated with intraneuronal inclusions these
would be highlighted by one or both of these antibodies
[38,39]. Any inclusions identified could then have been
further defined using other specific antibodies such as
lamin A/C or torsinA and the affected neurons would
have been immunophenotyped to determine whether
cholinergic neurons were affected as described in the
McNaught study. A limitation of our study was that,
due to the restricted tissue available for examination,
not all regions were present in each case. It therefore
remains a possibility that because of these sampling is-
sues we did not identify rare inclusions. Future studies
in systematically sampled cases would be required to
resolve this issue. Assessment of cell inclusions using a
reliable human specific torsinA antibody would be highly
desirable. We have previously tested 4 different antibodies:
torsinA [13,27,40], torsinA (TA913) [41], anti-torsinA
(ab34540) and torsinA (Santacruz s-20) using western
blots, IHC and immunofluorescence (unpublished data).
However, none of these was found to be reliable and
therefore could not be included in the study.
Despite the limitations of this study due to its retro-
spective nature and the restricted tissue availability our
observations support the previous findings that in primary
dystonia, there is no overt neurodegeneration or cell loss[23]. The pathological change of brainstem inclusions
reported in DYT1 dystonia [27] was not replicated in our
case series. Hence this study supports the previous find-
ings that overt cell loss or other obvious neuropathological
defects such as inclusions do not seem to be consistently
observed in DYT1 dystonia. However, subtle morpho-
logical defects of the type seen in the DYT1 mouse models
(e.g. abnormalities of neuronal size/shape, dendrite struc-
ture, spines, etc.) cannot be excluded. The analogy is simi-
lar to most human mental retardation syndromes, where
cell loss or inclusions are absent, but marked abnormalities
of neuritic structure are thought to play an important role.
The subtle morphological changes may not be identifiable
using current methods. In this regard, generation of cellu-
lar disease models using the induction of pluripotent stem
(iPS) cells from patient skin fibroblast has opened new ho-
rizons [42,43]. Understanding the cellular pathways influ-
enced by particular mutations and the neuronal networks
affected may inform future neuropathological studies.
Conclusion
We report a detailed neuropathological study of 7 DYT1
cases, the largest DYT1 case series yet investigated. The
anatomical regions implicated in dystonia showed no con-
sistent disease specific pathological features. Our observa-
tions support the previous findings that understanding the
biochemical changes may be more relevant than morpho-
logical alterations in isolated dystonia.
Additional file
Additional file 1: Table S1. Semi-quantitative summary of neuronal
loss (NL), gliosis pathology, Lewy bodies (LB), Tau pathology and Cerebral
amyloid angiopathy (CAA) in DYT1 cases.
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